Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution

British Journal of Clinical Pharmacology

Volumn 64, Issue 5, 2007, Pages 680-685

  Gumbs, Pearl D ^a,b   Verschuren, W M Monique ^b   Souverein, Patrick C ^a   Mantel Teeuwisse, Aukje K ^a   De Wit, G Ardine ^b   De Boer, Anthonius ^a   Klungel, Olaf H ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Division of Pharmacoepidemiology and Pharmacotherapy   (Netherlands)

Author keywords

Generic; Savings; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANAMNESIS; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DATA BASE; DRUG COST; DRUG INDUSTRY; DRUG POTENCY; DRUG SUBSTITUTION; DRUG USE; ECONOMIC EVALUATION; HUMAN; NETHERLANDS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SOCIOECONOMICS; THERAPY EFFECT;

COST SAVINGS; DRUG COSTS; DRUGS, GENERIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NETHERLANDS; PATIENT COMPLIANCE; PHARMACEUTICAL SERVICES; THERAPEUTIC EQUIVALENCY;

EID: 35248832088     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02958.x     Document Type: Article

References (18)

1. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet 1999 354 : 1202 4.
2. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA 2004 291 : 1850 6.
3. Moon JC, Bogle RG. Switching statins. BMJ 2006 332 : 1344 5.
4. Waterreus JJH. Lowering the reimbursement limit and therapeutic substitution (Verlaging GVS-limiet en therapeutische substitutie). Diemen, College voor zorgverzekeringen, 2006.
5. Total costs 2001-2005 per ATC-maingroup C. Cardiovascular (Totale kosten 2001-2005 per ATC-hoofdgroep C). Hartvaatstelsel, GIP College voor zorgverzekeringen, 2006.
6. G-standard descriptions (G-standaard beschrijvingen). Z-index, 2006.
7. Commissie Medicatiebewaking, Pharmacovigilance Commentaries. [Commentaren Medicatiebewaking] ed. Gier HD Houten, Health Base, 2005 956.
8. PHARMO-instituut. Efficiency first (Doelmatigheid Voorop). Utrecht, PHARMO, 2003 23.
9. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000 101 : 207 13.
10. Illingworth DR, Tobert JA. A review of clinical trials comparingHMG-CoA reductase inhibitors. Clin Ther 1994 16 : 366 85 discussion 365.
11. Statistics per theme. Individual and society. Population (Cijfers per thema: Mens en Maatschappij. Bevolking). Statistics Netherlands, 2006.
12. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 2006 40 : 15 20.
13. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998 352 : 1830 1.
14. van der Linde H. MOL undermines prescription freedom: Influence of industry bound medical opinion leaders is underestimated (MOL ondergraaft prescriptievrijheid: Invloed industriegebonden medische opinieleiders wordt onderschat). Med Contact 2006 61 : 1042 5.
15. SFK. Data and facts 2006 (Data en Feiten 2006). Den Haag, Stichting Farmaceutische Kengetallen, 2007 34.
16. Office of Fair Trading. The pharmaceutical price regulation scheme. Office of Fair Trading, 2007 114.
17. BOGIN. Highest civil court in the Netherlands decides bonus arrangements are admissible (Hoge raad acht bonusregelingen Menzis toelaatbaar). In : Bogin Bericht 2006 4.
18. BOGIN. Dutch GP society: the front door is unnecessarily open for expensive drugs (NHG: voordeur onnodig wagenwijd open voor dure geneesmiddelen). In : Bogin Bericht 2006 4.